Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17238555 | 1.00 | OPRM1 (0.43) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238551 | 1.00 | OPRM1 (0.43) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238560 | 0.90 | MMP1 (0.45) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238564 | 0.90 | MMP1 (0.45) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238563 | 0.90 | MMP1 (0.45) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238331 | 0.87 | MMP1 (0.43) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238332 | 0.87 | MMP1 (0.43) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL17238272 | 0.87 | MMP1 (0.43) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL15819471 | 0.87 | MMP1 (0.43) | OPRM1OPRL1MMP1MMP13CYP3A4 | |
| SCHEMBL15819650 | 0.83 | F9 (0.47) | OPRM1OPRL1MMP1MMP13CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-2934537-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9914727-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150329562-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322056-A1 | Factor IXa Inhibitors | F9, F12, F8 | OPRM1 1426/4885OPRL1 2254/4885MMP1 2351/4885 |
| US-20150329562-A1 | Factor IXa Inhibitors | F12, F9, F11 | OPRM1 3260/4885OPRL1 3823/4885MMP1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.